ALKBH3 regulates glycolysis and doxorubicin resistance in triple negative breast cancer

Post author:admin
Post published:July 12, 2025
Post category:uncategorized

This new article publication from Acta Pharmaceutica Sinica B, discusses how ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

Study highlights anti-inflammatory properties of herbal medicine, Erigeron breviscapus to treat osteoarthritis

Study confirms face masks’ effectiveness in reducing disease transmission, calls for improved public understanding

Heart damage during middle age linked to greater dementia risk in later life

Helpful Links

Subscribe To Us